Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.

Dendoncker K, Timmermans S, Vandewalle J, Eggermont M, Lempiäinen J, Paakinaho V, Van Hamme E, Dewaele S, Vandevyver S, Ballegeer M, Souffriau J, Van Wyngene L, Van Looveren K, Vanderhaeghen T, Beyaert R, De Bosscher K, Palvimo JJ, Van Montagu M, Libert C.

Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12942-12951. doi: 10.1073/pnas.1821565116. Epub 2019 Jun 10. Erratum in: Proc Natl Acad Sci U S A. 2019 Jul 22;:.

PMID:
31182584
2.

IRF2BP2 modulates the crosstalk between glucocorticoid and TNF signaling.

Manjur ABMK, Lempiäinen JK, Malinen M, Palvimo JJ, Niskanen EA.

J Steroid Biochem Mol Biol. 2019 Sep;192:105382. doi: 10.1016/j.jsbmb.2019.105382. Epub 2019 May 28.

PMID:
31145973
3.

Lack of androgen receptor SUMOylation results in male infertility due to epididymal dysfunction.

Zhang FP, Malinen M, Mehmood A, Lehtiniemi T, Jääskeläinen T, Niskanen EA, Korhonen H, Laiho A, Elo LL, Ohlsson C, Kotaja N, Poutanen M, Sipilä P, Palvimo JJ.

Nat Commun. 2019 Feb 15;10(1):777. doi: 10.1038/s41467-019-08730-z.

4.

Androgen receptor SUMOylation regulates bone mass in male mice.

Wu J, Movérare-Skrtic S, Zhang FP, Koskela A, Tuukkanen J, Palvimo JJ, Sipilä P, Poutanen M, Ohlsson C.

Mol Cell Endocrinol. 2019 Jan 5;479:117-122. doi: 10.1016/j.mce.2018.09.008. Epub 2018 Sep 24.

5.

Response: Commentary: Analysis of SUMO1-conjugation at synapses.

Daniel JA, Cooper BH, Palvimo JJ, Zhang FP, Brose N, Tirard M.

Front Cell Neurosci. 2018 May 1;12:117. doi: 10.3389/fncel.2018.00117. eCollection 2018. No abstract available.

6.

Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.

Lempiäinen JK, Niskanen EA, Vuoti KM, Lampinen RE, Göös H, Varjosalo M, Palvimo JJ.

Mol Cell Proteomics. 2017 Aug;16(8):1462-1474. doi: 10.1074/mcp.M117.067488. Epub 2017 Jun 13.

7.

Analysis of SUMO1-conjugation at synapses.

Daniel JA, Cooper BH, Palvimo JJ, Zhang FP, Brose N, Tirard M.

Elife. 2017 Jun 9;6. pii: e26338. doi: 10.7554/eLife.26338.

8.

Chromatin SUMOylation in heat stress: To protect, pause and organise?: SUMO stress response on chromatin.

Niskanen EA, Palvimo JJ.

Bioessays. 2017 Jun;39(6). doi: 10.1002/bies.201600263. Epub 2017 Apr 25. Review.

PMID:
28440894
9.

ZNHIT3 is defective in PEHO syndrome, a severe encephalopathy with cerebellar granule neuron loss.

Anttonen AK, Laari A, Kousi M, Yang YJ, Jääskeläinen T, Somer M, Siintola E, Jakkula E, Muona M, Tegelberg S, Lönnqvist T, Pihko H, Valanne L, Paetau A, Lun MP, Hästbacka J, Kopra O, Joensuu T, Katsanis N, Lehtinen MK, Palvimo JJ, Lehesjoki AE.

Brain. 2017 May 1;140(5):1267-1279. doi: 10.1093/brain/awx040.

PMID:
28335020
10.

Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.

Malinen M, Niskanen EA, Kaikkonen MU, Palvimo JJ.

Nucleic Acids Res. 2017 Jan 25;45(2):619-630. doi: 10.1093/nar/gkw855. Epub 2016 Sep 26.

11.

Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets.

Toropainen S, Niskanen EA, Malinen M, Sutinen P, Kaikkonen MU, Palvimo JJ.

Sci Rep. 2016 Sep 19;6:33510. doi: 10.1038/srep33510.

12.

Complete androgen insensitivity syndrome caused by a deep intronic pseudoexon-activating mutation in the androgen receptor gene.

Känsäkoski J, Jääskeläinen J, Jääskeläinen T, Tommiska J, Saarinen L, Lehtonen R, Hautaniemi S, Frilander MJ, Palvimo JJ, Toppari J, Raivio T.

Sci Rep. 2016 Sep 9;6:32819. doi: 10.1038/srep32819.

13.

SUMOylation of AMPKα1 by PIAS4 specifically regulates mTORC1 signalling.

Yan Y, Ollila S, Wong IPL, Vallenius T, Palvimo JJ, Vaahtomeri K, Mäkelä TP.

Nat Commun. 2015 Nov 30;6:8979. doi: 10.1038/ncomms9979.

14.

A new vertebrate SUMO enzyme family reveals insights into SUMO-chain assembly.

Eisenhardt N, Chaugule VK, Koidl S, Droescher M, Dogan E, Rettich J, Sutinen P, Imanishi SY, Hofmann K, Palvimo JJ, Pichler A.

Nat Struct Mol Biol. 2015 Dec;22(12):959-67. doi: 10.1038/nsmb.3114. Epub 2015 Nov 2.

PMID:
26524493
15.

Global SUMOylation on active chromatin is an acute heat stress response restricting transcription.

Niskanen EA, Malinen M, Sutinen P, Toropainen S, Paakinaho V, Vihervaara A, Joutsen J, Kaikkonen MU, Sistonen L, Palvimo JJ.

Genome Biol. 2015 Jul 28;16:153. doi: 10.1186/s13059-015-0717-y.

16.

Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells.

Malinen M, Toropainen S, Jääskeläinen T, Sahu B, Jänne OA, Palvimo JJ.

Mol Cell Endocrinol. 2015 Oct 15;414:91-8. doi: 10.1016/j.mce.2015.07.024. Epub 2015 Jul 26.

PMID:
26219822
17.

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykänen PS, Törmäkangas OP, Palvimo JJ, Kallio PJ.

Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007.

18.

Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells.

Lindqvist J, Imanishi SY, Torvaldson E, Malinen M, Remes M, Örn F, Palvimo JJ, Eriksson JE.

Mol Biol Cell. 2015 Jun 1;26(11):1971-84. doi: 10.1091/mbc.E14-12-1634. Epub 2015 Apr 7.

19.

Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.

Sundén H, Holland MC, Poutiainen PK, Jääskeläinen T, Pulkkinen JT, Palvimo JJ, Olsson R.

J Med Chem. 2015 Feb 12;58(3):1569-74. doi: 10.1021/jm501995n. Epub 2015 Feb 3.

PMID:
25646649
20.

SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin.

Toropainen S, Malinen M, Kaikkonen S, Rytinki M, Jääskeläinen T, Sahu B, Jänne OA, Palvimo JJ.

Nucleic Acids Res. 2015 Jan;43(2):848-61. doi: 10.1093/nar/gku1375. Epub 2014 Dec 30.

21.

A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity.

Kim DH, Xiao Z, Kwon S, Sun X, Ryerson D, Tkac D, Ma P, Wu SY, Chiang CM, Zhou E, Xu HE, Palvimo JJ, Chen LF, Kemper B, Kemper JK.

EMBO J. 2015 Jan 13;34(2):184-99. doi: 10.15252/embj.201489527. Epub 2014 Nov 25.

22.

Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.

Sutinen P, Rahkama V, Rytinki M, Palvimo JJ.

Mol Endocrinol. 2014 Oct;28(10):1719-28. doi: 10.1210/me.2014-1035. Epub 2014 Aug 15.

23.

Type II transmembrane serine protease gene variants associate with breast cancer.

Luostari K, Hartikainen JM, Tengström M, Palvimo JJ, Kataja V, Mannermaa A, Kosma VM.

PLoS One. 2014 Jul 16;9(7):e102519. doi: 10.1371/journal.pone.0102519. eCollection 2014.

24.

SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner.

Sutinen P, Malinen M, Heikkinen S, Palvimo JJ.

Nucleic Acids Res. 2014 Jul;42(13):8310-9. doi: 10.1093/nar/gku543. Epub 2014 Jun 30.

25.

Electrophilic lipid mediator 15-deoxy-Δ12,14-prostaglandin j2 modifies glucocorticoid signaling via receptor SUMOylation.

Paakinaho V, Kaikkonen S, Levonen AL, Palvimo JJ.

Mol Cell Biol. 2014 Sep;34(17):3202-13. doi: 10.1128/MCB.00748-14. Epub 2014 Jun 30.

26.

TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy.

Raatikainen S, Aaltomaa S, Palvimo JJ, Kärjä V, Soini Y.

Scand J Urol. 2015 Feb;49(1):51-7. doi: 10.3109/21681805.2014.909529. Epub 2014 Apr 30.

PMID:
24779451
27.

Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.

Poutiainen PK, Huhtala T, Jääskeläinen T, Petsalo A, Küblbeck J, Kaikkonen S, Palvimo JJ, Raunio H, Närvänen A, Peräkylä M, Juvonen RO, Honkakoski P, Laatikainen R, Pulkkinen JT.

Mol Cell Endocrinol. 2014 Apr 25;387(1-2):8-18. doi: 10.1016/j.mce.2014.02.008. Epub 2014 Feb 22.

PMID:
24565895
28.

Serum androgen bioactivity is low in children with premature adrenarche.

Liimatta J, Laakso S, Utriainen P, Voutilainen R, Palvimo JJ, Jääskeläinen T, Jääskeläinen J.

Pediatr Res. 2014 May;75(5):645-50. doi: 10.1038/pr.2014.21. Epub 2014 Feb 12.

PMID:
24522103
29.

Firefly luciferase inhibitor-conjugated peptide quenches bioluminescence: a versatile tool for real time monitoring cellular uptake of biomolecules.

Poutiainen PK, Rönkkö T, Hinkkanen AE, Palvimo JJ, Närvänen A, Turhanen P, Laatikainen R, Weisell J, Pulkkinen JT.

Bioconjug Chem. 2014 Jan 15;25(1):4-10. doi: 10.1021/bc4003713. Epub 2013 Dec 19.

PMID:
24341748
30.

SUMOylation regulates the chromatin occupancy and anti-proliferative gene programs of glucocorticoid receptor.

Paakinaho V, Kaikkonen S, Makkonen H, Benes V, Palvimo JJ.

Nucleic Acids Res. 2014 Feb;42(3):1575-92. doi: 10.1093/nar/gkt1033. Epub 2013 Nov 4.

31.

Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling.

Ronkainen VP, Tuomainen T, Huusko J, Laidinen S, Malinen M, Palvimo JJ, Ylä-Herttuala S, Vuolteenaho O, Tavi P.

Cardiovasc Res. 2014 Jan 1;101(1):69-77. doi: 10.1093/cvr/cvt226. Epub 2013 Oct 4.

PMID:
24095869
32.

Discovery of 5-benzyl-3-phenyl-4,5-dihydroisoxazoles and 5-benzyl-3-phenyl-1,4,2-dioxazoles as potent firefly luciferase inhibitors.

Poutiainen PK, Palvimo JJ, Hinkkanen AE, Valkonen A, Väisänen TK, Laatikainen R, Pulkkinen JT.

J Med Chem. 2013 Feb 14;56(3):1064-73. doi: 10.1021/jm301516q. Epub 2013 Jan 17.

PMID:
23286196
33.

Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.

Kaikkonen S, Paakinaho V, Sutinen P, Levonen AL, Palvimo JJ.

Mol Endocrinol. 2013 Feb;27(2):212-23. doi: 10.1210/me.2012-1313. Epub 2012 Nov 28.

34.

Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.

Berdel B, Nieminen K, Soini Y, Tengström M, Malinen M, Kosma VM, Palvimo JJ, Mannermaa A.

BMC Cancer. 2012 Nov 14;12:516. doi: 10.1186/1471-2407-12-516.

35.

Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors.

Malinen M, Jääskeläinen T, Pelkonen M, Heikkinen S, Väisänen S, Kosma VM, Nieminen K, Mannermaa A, Palvimo JJ.

Mol Cell Endocrinol. 2013 Jan 30;365(2):270-6. doi: 10.1016/j.mce.2012.10.028. Epub 2012 Nov 6.

PMID:
23142699
36.

FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™).

Belikov S, Öberg C, Jääskeläinen T, Rahkama V, Palvimo JJ, Wrange Ö.

Mol Cell Endocrinol. 2013 Jan 5;365(1):95-107. doi: 10.1016/j.mce.2012.10.002. Epub 2012 Oct 11.

PMID:
23063623
37.

Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus.

Rytinki M, Kaikkonen S, Sutinen P, Paakinaho V, Rahkama V, Palvimo JJ.

Mol Cell Biol. 2012 Oct;32(20):4195-205. Epub 2012 Aug 13.

38.

Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators.

Poutiainen PK, Oravilahti T, Peräkylä M, Palvimo JJ, Ihalainen JA, Laatikainen R, Pulkkinen JT.

J Med Chem. 2012 Jul 26;55(14):6316-27. doi: 10.1021/jm300233k. Epub 2012 Jul 11.

PMID:
22746350
39.

[Glucocorticoids and aetiopathogenesis of depression].

Viinamäki H, Lehto SM, Palvimo JJ, Harvima I, Valkonen-Korhonen M, Koivumaa-Honkanen H, Hintikka J, Kirsi H, Niskanen L.

Duodecim. 2012;128(10):1022-9. Review. Finnish.

PMID:
22724317
40.

Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.

Sundvall M, Korhonen A, Vaparanta K, Anckar J, Halkilahti K, Salah Z, Aqeilan RI, Palvimo JJ, Sistonen L, Elenius K.

J Biol Chem. 2012 Jun 29;287(27):23216-26. doi: 10.1074/jbc.M111.335927. Epub 2012 May 14.

41.

The androgen receptor.

Palvimo JJ.

Mol Cell Endocrinol. 2012 Apr 16;352(1-2):1-3. doi: 10.1016/j.mce.2012.01.016. Epub 2012 Jan 28. No abstract available.

PMID:
22300891
42.

Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth.

Jääskeläinen T, Makkonen H, Visakorpi T, Kim J, Roeder RG, Palvimo JJ.

Mol Cell Endocrinol. 2012 Mar 5;350(1):87-98. doi: 10.1016/j.mce.2011.11.025. Epub 2011 Dec 2.

PMID:
22155569
43.

Analysis of androgen receptor SUMOylation.

Rytinki MM, Kaikkonen S, Sutinen P, Palvimo JJ.

Methods Mol Biol. 2011;776:183-97. doi: 10.1007/978-1-61779-243-4_12.

PMID:
21796528
44.

Analysis of androgen receptor activity by reporter gene assays.

Makkonen H, Jääskeläinen T, Rytinki MM, Palvimo JJ.

Methods Mol Biol. 2011;776:71-80. doi: 10.1007/978-1-61779-243-4_5.

PMID:
21796521
45.

Interleukins 1α and 1β as regulators of steroidogenesis in human NCI-H295R adrenocortical cells.

Tkachenko IV, Jääskeläinen T, Jääskeläinen J, Palvimo JJ, Voutilainen R.

Steroids. 2011 Sep-Oct;76(10-11):1103-15. doi: 10.1016/j.steroids.2011.04.018. Epub 2011 May 8.

PMID:
21600230
46.

Steroid up-regulation of FKBP51 and its role in hormone signaling.

Jääskeläinen T, Makkonen H, Palvimo JJ.

Curr Opin Pharmacol. 2011 Aug;11(4):326-31. doi: 10.1016/j.coph.2011.04.006. Epub 2011 Apr 29. Review.

PMID:
21531172
47.

Androgen receptor: acting in the three-dimensional chromatin landscape of prostate cancer cells.

Makkonen H, Palvimo JJ.

Horm Mol Biol Clin Investig. 2011 Mar 1;5(1):17-26. doi: 10.1515/HMBCI.2010.055.

PMID:
25961240
48.

Overexpression of SUMO perturbs the growth and development of Caenorhabditis elegans.

Rytinki MM, Lakso M, Pehkonen P, Aarnio V, Reisner K, Peräkylä M, Wong G, Palvimo JJ.

Cell Mol Life Sci. 2011 Oct;68(19):3219-32. doi: 10.1007/s00018-011-0627-4. Epub 2011 Jan 21.

PMID:
21253676
49.

SUMO wrestling in cell movement.

Rytinki MM, Palvimo JJ.

Cell Res. 2011 Jan;21(1):3-5. doi: 10.1038/cr.2010.162. Epub 2010 Nov 23. No abstract available.

50.

Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.

Makkonen H, Kauhanen M, Jääskeläinen T, Palvimo JJ.

Mol Cell Endocrinol. 2011 Jan 1;331(1):57-65. doi: 10.1016/j.mce.2010.08.008. Epub 2010 Aug 20.

PMID:
20728506

Supplemental Content

Loading ...
Support Center